Subjects treated with epirubicin, expressing homozygous wild-type GSTO1 (GSTO1 A140, GSTO1 CC genotype), had a lower risk for bladder cancer recurrence (RFS) and a longer mean survival time (MST), as compared with the GSTO1 AC+AA genotype. Here, GSTO1 is linked to urinary bladder cancer.